Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Burkitt Lymphoma 2Recurrence 1Hematologic Neoplasms 1

Interventions

Surveys and Questionnaires 7Interviews as Topic 7Blood Specimen Collection 5Specimen Handling 4Exercise Test 4fludarabine 3Voriconazole 3Mental Status and Dementia Tests 3Bortezomib 3Standard of Care 2Observation 2Itraconazole 2Flow Cytometry 2Electronic Health Records 2Data Collection 2Antiviral Agents 2posaconazole 1liposomal amphotericin B 1isavuconazole 1glucarpidase 1fludarabine phosphate 1brexucabtagene autoleucel 1axicabtagene ciloleucel 1Whole-Body Irradiation 1Watchful Waiting 1Vincristine 1Valganciclovir 1Transplantation 1Tomography, X-Ray Computed 1Tomography, Optical Coherence 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Observational × Hematologic Neoplasms × Inotuzumab Ozogamicin × Clear all
NCT04307134 2025-12-31

Besponsa Post Marketing Surveillance Study

Pfizer

Completed
108 enrolled 39 charts
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡